glp-1 weight loss drug market news today Investing in Drugs: Eli Lilly, Novo Nordisk, and Viking Therapeutics in 2026 - and Statistics Weight-loss market to see 16

Although prospective studies specifically targeting PCOS + MASLD with pregnancy outcomes as the primary endpoint are currently lacking, a robust inference can be drawn based on the pathophysiological framework of MASLD and evidence from the general population: proactively identifying and reducing MASLD and ectopic fat load prior to pregnancy may be a key step in improving both periconception outcomes and long-term prognosis (68, 76)

Multiple CDMOs are already active across the GLP-1 value chain, including those involved in drug manufacturing, such as Corden Pharma (Astorg), Axplora (Bridgepoint) and AmbioPharma (Carlyle)

Who is Eligible for GLP-1 Agonists for Weight Loss

It helps regulate blood sugar levels by mimicking the actions of natural hormones in the body

Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions